ALLK Allakos Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLK

Price (delayed)

$3

Market cap

$262.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.53

Enterprise value

$230.91M

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab ...

Highlights
ALLK's EPS has surged by 77% year-on-year
Allakos's debt has decreased by 17% YoY
The net income has soared by 55% YoY but it has contracted by 10% from the previous quarter
The equity has declined by 36% year-on-year and by 13% since the previous quarter
The company's quick ratio fell by 30% YoY and by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allakos.com
Peers: OGN

Key stats

What are the main financial stats of ALLK
Market
Shares outstanding
87.48M
Market cap
$262.43M
Enterprise value
$230.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.18
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$176.88M
EBITDA
-$169.22M
Free cash flow
-$139.92M
Per share
EPS
-$1.53
Free cash flow per share
-$1.61
Book value per share
$2.54
Revenue per share
$0
TBVPS
$3.25
Balance sheet
Total assets
$283.5M
Total liabilities
$62.45M
Debt
$39M
Equity
$221.04M
Working capital
$194.83M
Liquidity
Debt to equity
0.18
Current ratio
9.31
Quick ratio
8.27
Net debt/EBITDA
0.19
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.6%
Return on equity
-62.3%
Return on invested capital
-65.6%
Return on capital employed
-68%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLK stock price

How has the Allakos stock price performed over time
Intraday
5.26%
1 week
38.89%
1 month
47.06%
1 year
-62.26%
YTD
-64.37%
QTD
32.16%

Financial performance

How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$177.29M
Net income
-$166.14M
Gross margin
N/A
Net margin
N/A
The net income has soared by 55% YoY but it has contracted by 10% from the previous quarter
The operating income has soared by 52% YoY but it has contracted by 10% from the previous quarter

Growth

What is Allakos's growth rate over time

Valuation

What is Allakos stock price valuation
P/E
N/A
P/B
1.18
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS has surged by 77% year-on-year
ALLK's price to book (P/B) is 82% less than its 5-year quarterly average of 6.1 and 25% less than its last 4 quarters average of 1.5
The equity has declined by 36% year-on-year and by 13% since the previous quarter

Efficiency

How efficient is Allakos business performance
The ROIC has grown by 48% YoY but it has contracted by 11% from the previous quarter
ALLK's return on equity is up by 47% year-on-year but it is down by 22% since the previous quarter
The return on assets has grown by 46% year-on-year but it has declined by 21% since the previous quarter

Dividends

What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLK.

Financial health

How did Allakos financials performed over time
Allakos's total assets has decreased by 32% YoY and by 11% from the previous quarter
The company's quick ratio fell by 30% YoY and by 8% QoQ
Allakos's debt is 82% less than its equity
The equity has declined by 36% year-on-year and by 13% since the previous quarter
ALLK's debt to equity is up by 29% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.